Diagrammed drawing of the lumbar vertebrae (lower spinal cord)

Chronic Pain Management

Move more patients from pain to relief

A large and costly problem, chronic pain affects approximately 1.5 billion people worldwide—more than heart disease, cancer and diabetes combined.1 That is why Abbott invests in the development of new therapy options and patient-centric system features that we believe will lead to an improved quality of life for more patients.

Whether your patients experience precise or pervasive* pain, our advanced approach to neuromodulation, with two superior and proven therapies, gives you the opportunity to provide better relief.**,2-4 Our proprietary dorsal root ganglion (DRG) therapy targets certain intractable focal pain of the lower limbs caused by CRPS,2 while our spinal cord stimulation (SCS) therapy, with revolutionary BurstDR™ stimulation,*** helps relieve pain felt broadly in the back, arms and/or legs. With Abbott, you can maximize patient outcomes by tailoring relief—because all pain is not equal.

Additionally, our radiofrequency ablation portfolio provides a minimally invasive alternative to back pain management.

Request Information

Related Portfolio

Learn about our additional portfolio for innovative chronic pain therapy.

Radiofrequency Therapy Portfolio

Manage pain earlier in the continuum of care with advancements in radiofrequency therapy technology backed by Abbott quality and innovation.

Two Superior Therapies. Because all pain is not equal.
Artistic drawing of the brain resembling a tree for BurstDR stimulation

BurstDR™ Stimulation: The Naturally Superior Choice

BurstDR™ stimulation,*** exclusively from Abbott, is a proven technology—inspired by nature—that revolutionizes neurostimulation by treating the whole patient.5-7 Not only does BurstDR stimulation offer your patients superior pain relief over tonic stimulation from chronic pain that is broadly felt in the back, arms and/or legs, it also relieves the suffering associated with chronic pain.3,4

A majority of patients say that they prefer BurstDR™ stimulation when compared to traditional tonic stimulation. 3,4

Learn more about BurstDR stimulation.

DRG Therapy: Designed to Deliver Targeted Stimulation

The pain therapy you choose matters. Now you can help patients with focal chronic intractable pain of the lower limbs due to causalgia or complex regional pain syndrome (CRPS) with a therapy specifically designed to relieve this type of pain.

Dorsal root ganglion (DRG) stimulation is a clinically proven therapy designed to deliver targeted stimulation and provide precise relief for patients with focal chronic pain conditions.2

Watch the video to see how DRG stimulation works, and learn about the Proclaim™ DRG Neurostimulation System.

Photograph of sun shining through green tree leaves

Transforming the Treatment of Chronic Pain

Inspired by the needs and challenges of patients with chronic pain, we believe that further innovation in the management of chronic pain will result in more effective outcomes. That is why Abbott invests in the development of objective clinical outcomes, new therapy options and patient-centric system features that we believe will lead to an improved quality of life for more patients.

Partner with us to treat more patients with better results and transform the lives of more patients suffering from chronic pain.

Contact your Abbott representative or request more information.


*Pain that is broadly felt in a large area of the body.
**When compared to traditional tonic spinal cord stimulation based on outcomes from the ACCURATE IDE study.
***BurstDR™ stimulation, patented technology exclusively from Abbott, is also referred to as Burst stimulation in clinical literature.
†Pain and suffering as measured by VAS.
1. Institute of Medicine. (2011). Relieving Pain in America Report 2011. Retrieved from http://www.iom.edu/Reports/2011/Relieving-Pain-in-America-A-Blueprint-for-Transforming-Prevention-Care-Education-Research.aspx
2. Deer, TR, Levy, RM, Kramer, J, et al. (2017). Dorsal root ganglion stimulation yielded higher treatment success rate for complex regional pain syndrome and causalgia at 3 and 12 months: a randomized comparative trial. Pain. 158(4): 669-681. http://dx.doi.org/10.1097/j.pain.0000000000000814 ACCURATE IDE STUDY, St. Jude Medical. (n=152)
3. St. Jude Medical. (2016). St. Jude Medical™ Proclaim™ Neurostimulation System Clinician’s Manual. Plano, TX. SUNBURST IDE study.
4. St. Jude Medical. (2016). St. Jude Medical™ Prodigy™ Neurostimulation System Programming and Reference Manual. Plano, TX. SUNBURST IDE study.
5. De Ridder, D., Vanneste, S., Plazier, M., & Vancamp, T. (2015). Mimicking the brain: Evaluation of St. Jude Medical’s Prodigy Chronic Pain System with Burst Technology. (n = 102). Expert Review of Medical Devices, 12(2), 143–150. http://dx.doi.org/10.1586/17434440.2015.985652
6. Van Havenbergh, T., Vancamp, T., Van Looy, P., Vanneste, S., & De Ridder, D. (2014). Spinal cord stimulation for the treatment of chronic back pain patients: 500-Hz vs. 1000-Hz burst stimulation. Neuromodulation18(1), 9-12. http://dx.doi.org/10.1111/ner.12252
7. Schu, S., Slotty, P. J., Bara, G., von Knop, M., Edgar, D., & Vesper J. (2014). A prospective, randomized, double-blind, placebo-controlled study to examine the effectiveness of burst spinal cord stimulation patterns for the treatment of failed back surgery syndrome. Neuromodulation17(5), 443-450. http://dx.doi.org/10.1111/ner/12197
8. Arnst, C., Licking, E., & Barrett, A. (1999). Conquering pain: New discoveries and treatments offer hope. Business Week3618, 102-106.
9. Guo, H. R., Tanaka, S., Halperin, W. E., & Cameron, L. L. (1999). Back pain prevalence in U.S. industry and estimates of lost workdays.  American Journal of Public Health, 89, 1029-1035. http://dx.doi.org/10.2105/ajph.89.7.1029

Orange 24 surrounded by headset, represents "Place an order"

Contact Customer Service

Our customer service experts can help with your product orders or questions.